Major influence of renal function on hyperlipidemia after living donor liver transplantation

Table 1 Patients’ characteristics in post-transplant hyperlipidemia group and non post-transplant hyperlipidemia group (means ± SD)

	PTHL group(n = 28)	Non-PTHL group (n = 87)	P value
Donor
Age (yr)	24.8 ± 4.3	24.0 ± 6.4	NS
Male/female (n)	27/1	80/7	NS
Cold ischemia time (h)	1.2 ± 0.5	1.1 ± 0.4	NS
GR/WR (%)	1.0 ± 0.2	1.1 ± 0.2	0.048
GV/SLV (%)	58.5 ± 5.6	62.6 ± 10.7	0.011
Hepatic steatosis n (%)	2 (7.1)	7 (8.0)	NS
Serum triglyceride (mg/dL)	90.9 ± 42.4	96.2 ± 45.0	NS
Serum cholesterol (mg/dL)	137.3 ± 30.9	135.7 ± 27.1	NS
Recipient
Age (yr)	45.4 ± 8.2	44.5 ± 10.6	NS
Male/female (n)	27/1	69/18	NS
Primary liver diseases n (%)
Cirrhosis	12 (42.9)	51 (58.6)	NS
Acute liver failure	9 (32.1)	19 (21.8)	NS
Hepatocellular carcinoma	7 (25)	17 (19.5)	NS
Pre-transplant metabolic status
BMI (kg/m2)	23.2 ± 3.16	21.9 ± 2.79	0.036
Smoking n (%)	7 (25)	19 (21.8)	NS
Alcohol abuse n (%)	3 (10.7)	13 (14.9)	NS
Diabetes mellitus n (%)	2 (7.1)	4 (4.6)	NS
Hypertension n (%)	3 (10.7)	5 (5.7)	NS
Hyperlipidemia n (%)	4 (14.3)	15 (17.2)	NS
Pre-transplant MELD score	23.8 ± 12.4	20.1 ± 9.6	NS
Total bilirubin (mg/dL)	14.2 (1.0-36.5)	12.8 (0.8-33.6)	NS
International normalized ratio	1.6 ± 1.1	1.4 ± 0.6	NS
Serum creatinine (mg/dL)	0.9 (0.5-4.0)	0.7 (0.4-4.5)	0.004
Post-transplant tacrolimus level (ng/mL)
Month 1	8.1 ± 2.8	9.8 ± 4.6	NS
Month 3	9.2 ± 2.6	8.3 ± 2.6	NS
Month 6	6.7 ± 2.2	7.7 ± 2.7	NS
Follow-up period (yr)	2.7 ± 1.2	2.6 ± 0.9	NS

PTHL: Post-transplant hyperlipidemia; GR/WR: Graft-to-recipient weight ratio; GV/SLV: Graft volume/standard liver volume; BMI: Body mass index; MELD: Model for end-stage liver disease; NS: Not significant.